Method for genotyping clonotype profiles using sequence tags

• US 10,077,473 B2
• Filed: 06/01/2017
• Issued: 09/18/2018
• Est. Priority Date: 07/01/2013
• Status: Active Grant

• Current Assignee: Adaptive Biotechnologies Corp.
• Original Assignee: Adaptive Biotechnologies Corp.
• Inventors: Asbury, Thomas, Hervold, Kieran, Kotwaliwale, Chitra, Faham, Malek, Moorhead, Martin, Weng, Li, Wittkop, Tobias, Zheng, Jianbiao
• Primary Examiner(s): Horlick, Kenneth R
• Application Number:
  US15/611,093
• Publication Number:
  US 20170335390A1
• Time in Patent Office: 474 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2525/161 incorporating target specific and non-target specific sites
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment
• CPC Class Codes: G16Z 99/00 Subject matter not provided for in other main groups of this subclass
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The invention is directed to sequence-based profiling of populations of nucleic acids by multiplex amplification and attachment of one or more sequence tags to target nucleic acids and/or copies thereof followed by high-throughput sequencing of the amplification product. In some embodiments, the invention includes successive steps of primer extension, removal of unextended primers and addition of new primers either for amplification (for example by PCR) or for additional primer extensions. Some embodiments of the invention are directed to minimal residual disease (MRD) analysis of patients being treated for cancer. Sequence tags incorporated into sequence reads provide an efficient means for determining clonotypes and at the same time provide a convenient means for detecting carry-over contamination from other samples of the same patient or from samples of a different patient which were tested in the same laboratory.

Claims

1. A method of detecting minimal residual disease in a patient being treated for cancer, the method comprising the steps of:

(a) attaching sequence tags to each of a plurality of recombined nucleic acids in a sample containing T-cells and/or B-cells and/or cell free DNA or RNA obtained from the patient to form tag-nucleic acid conjugates, wherein at least one recombined nucleic acid or copies thereof have different sequence tags attached and are characteristic of the cancer of the patient, and wherein the attaching comprises;

(i) combining in a reaction mixture under primer extension conditions a first set of primers with the sample, wherein each primer of the first set comprises a receptor-specific portion, a 5′

-non-complementary end containing a first primer binding site and a sequence tag disposed between the receptor-specific portion and the first primer binding site, wherein the receptor-specific portion anneals to a different recombined nucleic acid at a first predetermined location and is extended to form a first extension product; and

(ii) adding to the reaction mixture under primer extension conditions a second set of primers, wherein each primer of the second set has a receptor-specific portion, wherein the receptor-specific portion anneals to the first extension product at a second predetermined location, and wherein each primer of the second set is extended to form a second extension product, wherein each second extension product comprises a first primer binding site, sequence tag, and recombined nucleic acid encoding a portion of a T cell receptor chain or a B cell receptor chain;

(b) amplifying the tag-nucleic acid conjugates;

(c) sequencing a sample of the tag-nucleic acid conjugates to provide sequence reads each comprising a tag sequence and a recombined nucleic acid sequence;

(d) aligning sequence reads having like tag sequences to form groups of sequence reads having identical sequence tags;

(e) coalescing recombined nucleic acid sequences of groups to determine clonotypes, wherein groups of sequence reads are coalesced into different clonotypes whenever said groups of recombined nucleic acid sequences are distinct with a likelihood of at least 99.9 percent; and

(f) detecting in a clonotype profile the presence, absence and/or level of clonotypes correlated with the cancer of the patient, thereby detecting the minimal residual disease in a patient.

2. The method of claim 1, wherein the amplifying comprises performing a polymerase chain reaction in the reaction mixture to form an amplicon, the polymerase chain reaction using forward primers specific for the first primer binding site and reverse primers specific for the second set of primers.

3. The method of claim 1, wherein the recombined nucleic acids comprise recombined nucleic acids encoding TCRβ

, TCRδ and

TCRγ

chains, and wherein the primers of the first set and the primers of the second set comprise primers that flank regions of the recombined nucleic acids encoding VDJ regions of TCRβ and

TCR and primers that flank VJ regions of TCRγ

.

4. The method of claim 1, wherein the recombined nucleic acids comprise recombined nucleic acids encoding IgH and IgK and wherein the primers of the first set and the primers of the second set comprise primers that flank regions of the recombined nucleic acids encoding VDJ regions of IgH, DJ regions of IgH and VJ regions of IgK.

5. The method of claim 4, wherein the primers of the first set or the second set include at least one nested set of primers specific for a plurality of different primer binding sites in V regions of said IgH chains.

6. The method of claim 1, further comprising a step of removing from the reaction mixture non-extended primers of the first set and the second set.

7. The method of claim 6, wherein the step of removing comprises adding an enzyme with exonuclease activity to the reaction mixture.

8. The method of claim 1, wherein the annealing and extension of the primers of the first set is repeated after melting the first extension product.

9. The method of claim 1, wherein the annealing and extension of the primers of the second set is repeated after melting the second extension product.

10. The method of claim 1, wherein the sequence tags are mosaic tags, wherein the mosaic tags comprise alternating constant regions and variable regions.

11. The method of claim 1, wherein the first predetermined location is a V region.

12. The method of claim 11, wherein the receptor specific portion of each of the primers of the first set anneals to different non-overlapping positions in the V region.

13. The method of claim 1, wherein the second predetermined location is a J region or a C region.

14. The method of claim 13, wherein the receptor specific portion of each of the primers of the second set anneals to different non-overlapping positions in the J region.

15. The method of claim 13, wherein the receptor specific portion of each of the primers of the second set anneals to a single primer binding site in the J region.

16. The method of claim 2, wherein the forward primers and/or the reverse primers comprise a 5′

non-complementary end comprising a sample tag.